Definition

A preparation of autologous tumor infiltrating lymphocytes (TILs) engineered to express membrane-bound interleukin-12 (mbIL-12), with potential immunomodulating and antineoplastic activities. The TILs are isolated from an autologous tumor sample and engineered to express mbIL-12. Upon infusion of the autologous mbIL-12-expressing TILs GT202 back into the patient, the cells specifically recognize, target and kill the patient’s tumor cells. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-lymphocyte (CTL) responses, further killing tumor cells.